PL3606546T3 - Konstrukt genetyczny do zastosowania w leczeniu zaburzenia neurodegeneracyjnego lub udaru - Google Patents
Konstrukt genetyczny do zastosowania w leczeniu zaburzenia neurodegeneracyjnego lub udaruInfo
- Publication number
- PL3606546T3 PL3606546T3 PL18715911T PL18715911T PL3606546T3 PL 3606546 T3 PL3606546 T3 PL 3606546T3 PL 18715911 T PL18715911 T PL 18715911T PL 18715911 T PL18715911 T PL 18715911T PL 3606546 T3 PL3606546 T3 PL 3606546T3
- Authority
- PL
- Poland
- Prior art keywords
- stroke
- treatment
- genetic construct
- neurodegenerative disorder
- neurodegenerative
- Prior art date
Links
- 230000002068 genetic effect Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Toxicology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1705484.2A GB201705484D0 (en) | 2017-04-05 | 2017-04-05 | Genetic construct |
| PCT/GB2018/050824 WO2018185468A1 (en) | 2017-04-05 | 2018-03-28 | Genetic construct for use in the treatment of neurodegenerative disorder or stroke |
| EP18715911.6A EP3606546B1 (en) | 2017-04-05 | 2018-03-28 | Genetic construct for use in the treatment of neurodegenerative disorder or stroke |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3606546T3 true PL3606546T3 (pl) | 2021-11-08 |
Family
ID=58682577
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL18715911T PL3606546T3 (pl) | 2017-04-05 | 2018-03-28 | Konstrukt genetyczny do zastosowania w leczeniu zaburzenia neurodegeneracyjnego lub udaru |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20200046850A1 (pl) |
| EP (1) | EP3606546B1 (pl) |
| JP (1) | JP7296321B2 (pl) |
| KR (1) | KR102616629B1 (pl) |
| CN (1) | CN110809476B (pl) |
| AU (1) | AU2018248651B2 (pl) |
| CA (1) | CA3058549A1 (pl) |
| ES (1) | ES2881176T3 (pl) |
| GB (1) | GB201705484D0 (pl) |
| MX (1) | MX2019012000A (pl) |
| PL (1) | PL3606546T3 (pl) |
| PT (1) | PT3606546T (pl) |
| RU (1) | RU2757932C2 (pl) |
| WO (1) | WO2018185468A1 (pl) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020006149A2 (pt) * | 2017-09-27 | 2020-10-20 | Sigilon Therapeutics, Inc. | célula ativa manipulada, elemento implantável, e, composição farmacêutica. |
| EP3898982A2 (en) * | 2018-12-19 | 2021-10-27 | Versameb AG | Rna encoding a protein |
| JP7524158B2 (ja) | 2019-03-04 | 2024-07-29 | 公益財団法人東京都医学総合研究所 | Ｔｒｋ断片をコードする核酸構築物、及びその利用 |
| US20220267794A1 (en) * | 2019-03-27 | 2022-08-25 | Sigilon Therapeutics, Inc. | Compositions, devices, and methods for treating fabry disease |
| GB202004832D0 (en) * | 2020-04-01 | 2020-05-13 | Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa | Therapeutic agaents, pharmaceutical compositions, and associated biomarkers |
| CN114933657B (zh) * | 2021-08-25 | 2024-02-02 | 上海交通大学医学院 | 神经生长因子突变体重组蛋白及其应用 |
| CN118256562A (zh) * | 2022-12-26 | 2024-06-28 | 科辉智药(深圳)新药研究中心有限公司 | 一种用于中枢神经系统疾病治疗的基因序列构建体及其应用 |
| AU2024214634A1 (en) | 2023-02-02 | 2025-06-26 | Quethera Limited | Recombinant adeno-associated virus vector |
| EP4413993A1 (en) * | 2023-02-10 | 2024-08-14 | Dompe' Farmaceutici S.P.A. | Method of obtaining recombinant human brain-derived neurotrophic factor |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2588221C (en) * | 1999-06-08 | 2013-07-09 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US20030124095A1 (en) * | 2001-12-31 | 2003-07-03 | Regents Of The University Of California | Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex |
| US9265843B2 (en) * | 2008-03-27 | 2016-02-23 | The Ohio State University | Treatment of metabolic-related disorders using hypothalamic gene transfer of BDNF and compositions therefor |
| CN105641694B (zh) * | 2008-12-19 | 2020-08-14 | H.隆德贝克有限公司 | 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节 |
| ES2694592T3 (es) * | 2012-03-15 | 2018-12-21 | Curna, Inc. | Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado del cerebro (BDNF) por inhibición del transcrito antisentido natural de BDNF |
| GB2547179A (en) * | 2015-10-26 | 2017-08-16 | Quethera Ltd | Genetic construct |
-
2017
- 2017-04-05 GB GBGB1705484.2A patent/GB201705484D0/en not_active Ceased
-
2018
- 2018-03-28 JP JP2019554630A patent/JP7296321B2/ja active Active
- 2018-03-28 MX MX2019012000A patent/MX2019012000A/es unknown
- 2018-03-28 PT PT187159116T patent/PT3606546T/pt unknown
- 2018-03-28 CA CA3058549A patent/CA3058549A1/en active Pending
- 2018-03-28 EP EP18715911.6A patent/EP3606546B1/en active Active
- 2018-03-28 KR KR1020197032606A patent/KR102616629B1/ko active Active
- 2018-03-28 AU AU2018248651A patent/AU2018248651B2/en active Active
- 2018-03-28 PL PL18715911T patent/PL3606546T3/pl unknown
- 2018-03-28 ES ES18715911T patent/ES2881176T3/es active Active
- 2018-03-28 RU RU2019131098A patent/RU2757932C2/ru active
- 2018-03-28 CN CN201880023931.XA patent/CN110809476B/zh active Active
- 2018-03-28 WO PCT/GB2018/050824 patent/WO2018185468A1/en not_active Ceased
- 2018-03-28 US US16/497,412 patent/US20200046850A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2881176T3 (es) | 2021-11-29 |
| RU2757932C2 (ru) | 2021-10-25 |
| EP3606546B1 (en) | 2021-04-28 |
| EP3606546A1 (en) | 2020-02-12 |
| RU2019131098A3 (pl) | 2021-07-27 |
| RU2019131098A (ru) | 2021-05-05 |
| WO2018185468A1 (en) | 2018-10-11 |
| CN110809476B (zh) | 2024-02-27 |
| JP7296321B2 (ja) | 2023-06-22 |
| PT3606546T (pt) | 2021-07-12 |
| KR20200005549A (ko) | 2020-01-15 |
| JP2020516244A (ja) | 2020-06-11 |
| CA3058549A1 (en) | 2018-10-11 |
| AU2018248651B2 (en) | 2024-07-25 |
| CN110809476A (zh) | 2020-02-18 |
| GB201705484D0 (en) | 2017-05-17 |
| KR102616629B1 (ko) | 2023-12-21 |
| US20200046850A1 (en) | 2020-02-13 |
| AU2018248651A1 (en) | 2019-10-17 |
| MX2019012000A (es) | 2020-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL3606546T3 (pl) | Konstrukt genetyczny do zastosowania w leczeniu zaburzenia neurodegeneracyjnego lub udaru | |
| IL264641A (en) | Acetyl-leucine for use in the treatment of neurodegenerative diseases | |
| IL263521A (en) | Combination therapy | |
| GB201411496D0 (en) | Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy | |
| IL265406B (en) | combined treatment | |
| GB201608885D0 (en) | Treatment | |
| GB201711190D0 (en) | Use of cannabininoids in the treatment of a neurodegenerative disease or disorder | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| PL3160464T3 (pl) | 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych | |
| GB201608797D0 (en) | Therapeutic use | |
| LT3423060T (lt) | Imatinibas, skirtas naudoti insulto gydymui | |
| IL250182A0 (en) | chlorinator | |
| ZA201901578B (en) | Combinations including abx196 for the treatment of cancer | |
| GB201604318D0 (en) | Combination therapy | |
| GB201604316D0 (en) | Combination therapy | |
| GB201603653D0 (en) | Combination Therapy | |
| IL265340A (en) | Combination therapy | |
| ZA201901505B (en) | Phenylalanine-free protein for the treatment of pku | |
| IL259383A (en) | A compound for use in the prevention and treatment of neurodegenerative diseases | |
| GB201609735D0 (en) | Combination therapy | |
| GB201518002D0 (en) | Ketamine for the treatment of somatoform pain disorder | |
| PT3270913T (pt) | Citalopram ou escitalopram para utilização no tratamento de doenças neurodegenerativas | |
| GB201617107D0 (en) | Treatment | |
| GB201612260D0 (en) | Treatment | |
| GB201612193D0 (en) | Treatment |